“…BMS is not a specific disease entity but rather it is the manifestation of a range of aetiologies 23,24 and, for the treating clinician, it has remained an enigma because defined pathological lesions or processes are usually not evident 25 . Thus, unsurprisingly, current treatments are not reliably effective 26 . We have previously shown that alpha‐lipoic acid (ALA; Tiobec), a potent antioxidant mitochondrial coenzyme, the trometamol salt of thioctic acid, essential for various reactions of the Krebs cycle and glycolysis, regenerating, through the oxidation–reduction cycle, other antioxidants such as vitamin C and E, increasing the level of intracellular glutathione, and stimulating the production of ‘nerve‐growth factors’, 27 can be effective in some patients with BMS 20,21 …”